ArticleBMC gastroenterology2025
MMP11 predicts colorectal cancer outcomes and its inhibitor RXP03 exerts anti-tumor effects via apoptosis activation.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeMMP11 exhibits significant overexpression in various cancers; however, its role in colorectal cancer (CRC) remains poorly understood. This study aimed to investigate the relationship between MMP11 and the prognosis of colorectal cancer and to evaluate the therapeutic potential of an MMP11 inhibitor.
methodsOur study employed an integrative bioinformatics approach utilizing TIMER, GEPIA, UALCAN, and HPA datasets to comprehensively assess MMP11 expression patterns and their correlation with clinicopathological characteristics and tumor-infiltrating immune cells (TIICs) in colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ). Overall survival (OS) data for CRC were extracted from the The Cancer Genome Atlas (TCGA). To investigate the therapeutic potential of MMP11 inhibition, we treated HCT116 and SW480 CRC cell lines with the MMP11 inhibitor RXP03. Colony formation and transwell assays were used to evaluated the proliferation and invasion abilities of CRC cells, while apoptosis was measured via TUNEL staining and flow cytometry. Additionally, xenograft tumor models were used to assess the tumor-suppressive effects of MMP11 inhibition.
resultsMMP11 expression was significantly upregulated in COAD and READ specimens compared to normal controls, and was correlated with age, tumor stage, histological subtype and nodal metastasis status. Kaplan-Meier survival analysis indicated that high MMP11 expression was an independent prognostic factor for poorer overall survival in CRC. TIMER analysis revealed that MMP11 transcription was strongly positively correlated with several TIICs, including CD4 + T cells, macrophages, and dendritic cells. Furthermore, MMP11 expression exhibited significant positive correlations with the infiltration levels of B7-H3 and TIM3 in CRC. In vitro experiments revealed that RXP03 significantly inhibited the proliferation and invasion of CRC cells and induced apoptosis. Xenograft experiments further demonstrated that RXP03 markedly suppressed the growth of colorectal tumors in vivo.
conclusionMMP11 expression is associated with survival outcomes and levels of TIICs in CRC patients, suggesting its potential as a prognostic biomarker for CRC. Moreover, therapeutic intervention with the MMP11 inhibitor RXP03 demonstrates anti-tumor efficacy against CRC in both in vitro and in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.